News Related to International Diabetes Federation

Related coverage linked through entity extraction aliases.

Zydus Lifesciences Launches Semaglutide, Aflibercept Biosimilar; USFDA Clears Ahmedabad Plant

Feb 26, 2026

Zydus Lifesciences plans to launch Semaglutide injection in India after patent expiry and introduced ANYRA, India's first indigenous Aflibercept biosimilar. The USFDA cleared the company's Ahmedabad injectable facility with zero observations.

Dr Reddy's to Launch Generic Semaglutide 'Obeda' in India as Patent Expires in March

Feb 25, 2026

Indian drugmaker Dr Reddy's Laboratories is preparing to launch its generic semaglutide injection under the brand name Obeda in March 2026, as patent protection expires in India. The company plans to price it up to 60% below branded products.